KR900005996A - 자기면역 질환의 치료 또는 예방을 위한 면역독소 - Google Patents

자기면역 질환의 치료 또는 예방을 위한 면역독소 Download PDF

Info

Publication number
KR900005996A
KR900005996A KR1019890015214A KR890015214A KR900005996A KR 900005996 A KR900005996 A KR 900005996A KR 1019890015214 A KR1019890015214 A KR 1019890015214A KR 890015214 A KR890015214 A KR 890015214A KR 900005996 A KR900005996 A KR 900005996A
Authority
KR
South Korea
Prior art keywords
epitope
immunotoxin
leu
present
protein
Prior art date
Application number
KR1019890015214A
Other languages
English (en)
Other versions
KR0151851B1 (ko
Inventor
안토니우스 마리아 베르호일 헤르마누스
Original Assignee
에이.지.제이.베르미렌·에프.지.엠.헤르만스
악조 엔.브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이.지.제이.베르미렌·에프.지.엠.헤르만스, 악조 엔.브이 filed Critical 에이.지.제이.베르미렌·에프.지.엠.헤르만스
Publication of KR900005996A publication Critical patent/KR900005996A/ko
Application granted granted Critical
Publication of KR0151851B1 publication Critical patent/KR0151851B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

자기면역 질환의 치료 또는 예방을 위한 면역독소
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 특정의 자기 면역 질환에 대해 특징이 있는 T-임파구에 의해 인지되는 에피토프(epitope)나 그것의 교차-반응성 동족물을 포함하며, 상기의 에피토프나 그것의 교차 반응성 동족물이 세포독소 물질에 연결된 면역 독소를 특징으로 하는 자기 면역 질환의 예방 또는 치료용 면역 독소.
  2. 제1항에 있어서, 에피토프가 관절 연골의 단백질에 존재하는 것을 특징으로 하는 류마토이드성 관절염의 예방 또는 치료용 면역 독소.
  3. 제2항에 있어서, 상기 에피토프가 아미노산 서열 Thr-Ala-Val-Val-Ala-Leu-Gli-Leu-Gln을 갖는 것을 특징으로 하는 면역 독소.
  4. 제1항에 있어서, 상기 에피토프가 미코박테리움의 65KD 단백질에 존재하는 것을 특징으로 하는 류마토이드성 관절염의 예방 또는 치료용 면역 독소.
  5. 제4항에 있어서, 상기 에피토프가 아미노산 서열 Thr-Phe-Gly-Leu-Gln-Leu-Gln-Leu-Thr을 갖는 것을 특징으로 하는 면역 독소.
  6. 제1항에 있어서, 상기 에피토프가 미엘린 염기성 단백질에 존재하는 것을 특징으로 하는 다발성 경화증의 예방 또는 치료용 면역 독소.
  7. 제1항에 있어서, 상기 에피토프가 아세틸콜린 수용체에 존재하는 것을 특징으로 하는 중증성 근 무력증의 예방 또는 치료용 면역 독소.
  8. 제1항 내지 제7항중 어느 한 항에 있어서, 세포독소물질이 리보자임-불활성화 단백질임을 특징으로 하는 면역 독소.
  9. 제1항 내지 제7항중 어느 한 항에 있어서, 세포독소물질이 방사능 동위 원소임을 특징으로 하는 면역 독소.
  10. 제1항 내지 제9항에 의한 면역 독소를 하나 이상 생물학적 활성 성분으로 포함하는 약학적 제제.
  11. 에피토프나 그것의 교차-반응성 동족물이 집적적으로 또는 링커를 통해 세포 독소 물질에 연결된 것을 특징으로 하는 제1항 내지 제9항중 어느 한 항에 의한 면역 독소의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890015214A 1988-10-21 1989-10-21 자기면역 질환의 치료 또는 예방을 위한 면역독소 KR0151851B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP88-202349.2 1987-10-21
EP88202349 1988-10-21
EP88.202349.2 1988-10-21

Publications (2)

Publication Number Publication Date
KR900005996A true KR900005996A (ko) 1990-05-07
KR0151851B1 KR0151851B1 (ko) 1998-10-15

Family

ID=8199870

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890015214A KR0151851B1 (ko) 1988-10-21 1989-10-21 자기면역 질환의 치료 또는 예방을 위한 면역독소

Country Status (15)

Country Link
EP (1) EP0365087B1 (ko)
JP (1) JP2807506B2 (ko)
KR (1) KR0151851B1 (ko)
AT (1) ATE78407T1 (ko)
AU (1) AU625802B2 (ko)
CA (1) CA2000999A1 (ko)
DE (1) DE68902212T2 (ko)
DK (1) DK523589A (ko)
ES (1) ES2051989T3 (ko)
FI (1) FI100305B (ko)
GR (1) GR3006048T3 (ko)
IE (1) IE61831B1 (ko)
NZ (1) NZ231095A (ko)
PT (1) PT92071B (ko)
ZA (1) ZA897895B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100346059B1 (ko) * 1999-12-30 2002-07-24 주식회사 효성 폴리에스테르 섬유의 제조방법

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012145A1 (en) * 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
WO2000009155A1 (en) 1998-08-11 2000-02-24 Rush-Presbyterian-St.Luke's Medical Center Methods and compositions for preventing anti-gal production in xenograft recipients
ES2370535T3 (es) * 2006-11-23 2011-12-19 Cadila Pharmaceuticals Limited Antagonista de poli-tlr.
WO2018031947A1 (en) 2016-08-12 2018-02-15 Immunowork, Llc Diagnosis, prevention, and/or treatment of autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
DE3513572A1 (de) * 1985-04-16 1986-10-16 Karl Prof. Dr.med. 7302 Ostfildern Theurer Herstellung von praeparaten zur spezifischen beeinflussung der humoralen und zellulaeren immunreaktion
NL8701163A (nl) * 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100346059B1 (ko) * 1999-12-30 2002-07-24 주식회사 효성 폴리에스테르 섬유의 제조방법

Also Published As

Publication number Publication date
AU4359589A (en) 1990-04-26
GR3006048T3 (ko) 1993-06-21
FI895005A0 (fi) 1989-10-20
JP2807506B2 (ja) 1998-10-08
DK523589D0 (da) 1989-10-20
JPH02169523A (ja) 1990-06-29
DE68902212T2 (de) 1993-05-27
ES2051989T3 (es) 1994-07-01
ATE78407T1 (de) 1992-08-15
EP0365087A1 (en) 1990-04-25
FI100305B (fi) 1997-11-14
DE68902212D1 (de) 1992-08-27
EP0365087B1 (en) 1992-07-22
PT92071B (pt) 1995-06-30
PT92071A (pt) 1990-04-30
DK523589A (da) 1990-04-22
AU625802B2 (en) 1992-07-16
IE61831B1 (en) 1994-11-30
KR0151851B1 (ko) 1998-10-15
NZ231095A (en) 1992-03-26
CA2000999A1 (en) 1990-04-21
ZA897895B (en) 1990-07-25
IE893324L (en) 1990-04-21

Similar Documents

Publication Publication Date Title
EP0306943B1 (en) Immunconjugates joined by thioether bonds having reduced toxicity and improved selectivity
Lemley et al. Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo
MY108519A (en) Novel antibodies reactive with human carcinomas.
KR937000141A (ko) 비면역 유발성 운반체에 결합된 면역 유발원의 t세포 에피토프-결핍 유사물을 포함하며 면역유발원에 대한 체액성 아네르기를 유발하는 조성물
CO4850562A1 (es) Proceso para producir una preparacion concentrada de anticuerpos
PT651646E (pt) Conjugados terapeuticos de toxinas e farmacos
ATE162403T1 (de) Modifizierte antikörper mit kontrollierter clearance-zeit
ATE454124T1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
FR2437213A1 (fr) Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
ZA828048B (en) Novel anti-cancer drugs for the treatment of leukaemias t constituted by the chain a of ricin and a specific monoclonal antibody
PH18031A (en) Immunoglobulin conjugates,process for preparing them and pharmaceutical composition containing the same
IL97776A (en) Composition comprising a conjugate of a ZME antibody and a biological response modifier
KR900005996A (ko) 자기면역 질환의 치료 또는 예방을 위한 면역독소
DE69007799D1 (de) Pharmazeutische antigen-antikörper-komplexe enthaltende zusammensetzungen und deren anwendungen.
ATE67507T1 (de) Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
EP0493446A4 (en) Treatment of autoimmune disease
JPH0720883B2 (ja) 免疫毒素及びその製造方法
IL93425A0 (en) Modified pseudomonas exotoxin,its production and pharmaceutical compositions containing it
Stirpe et al. Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin
Morgan Jr et al. Immunotoxins of Pseudomonas exotoxin A (PE): effect of linkage on conjugate yield, potency, selectivity and toxicity
Gasanov et al. In vitro evaluation of Pyrularia thionin—anti-CD5 immunotoxin
FR2701952B1 (fr) Nouveaux dérivés cyclopeptidiques de l'angiopeptine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
WO1996041608A3 (en) Pyrularia thionin containing immunotoxins and immunotoxin-like conjugates
Blakey et al. What's new: Immunotoxins
Newell et al. The differential ultrastructural localization of immunoglobulin heavy and light chains in human haematopoietic cell lines

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee